Meeting
2020 Genitourinary Cancers Symposium
Predicting toxicity-related docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer (mCRPC) using open phase III trial data.
Authors
Anish B. Parikh
Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center-James Cancer Hospital, Columbus, OH
Anish B. Parikh , Alberto Martini , John Sfakianos , Matt D. Galsky , William K. Oh , Che-Kai Tsao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 75)
Abstract #
75
Poster Bd #
C19
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials.
First Author: Guru Sonpavde
Poster
2015 Genitourinary Cancers Symposium
Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Guru Sonpavde
Poster
2023 ASCO Genitourinary Cancers Symposium
Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.
First Author: Padmanee Sharma
First Author: Matthew Raymond Smith